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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2014, KaohsiuAbstract The aim of this study was to evaluate the local recurrence and distant metastasis
rates for urothelial carcinoma of the bladder after radical cystectomy and to identify the pre-
dictive factors for local recurrence and distant metastasis. The study population was 347
consecutive patients treated with radical cystectomy for urothelial carcinoma of the bladder
at our institution. Local recurrence, distant metastasis, and both local and distant recurrence
rates were 49 (14.1%) months, 96 (27.7%) months, and 17 (4.9%) months, respectively. The
mean follow-up times to recurrence were 14.37  13.25 months (range, 2e60 months) and
14.43  15.72 months (range, 2e109 months) for local recurrence and distant metastasis,
respectively (p Z 0.808). The mean post-recurrence disease-specific survival (PRDSS) times
for local, distant, and both local and distant recurrences were 17.82  3.18 months,
4.16  0.39 months, and 11.41  2.73 months, respectively (p < 0.001). The predictive factors
for local recurrence and distant metastasis were stage and nodal involvement (p < 0.001). Sex,
grade, lymphovascular invasion (LVI), carcinoma in situ (CIS), and lymph node density (LND;
10% cut-off value) were not predictors for recurrence in the results of the multivariate anal-
ysis. The current study demonstrated that stage and pathological nodal involvement were in-
dependent predictors of local recurrence and distant metastasis. The results of this study
suggest that the early diagnosis and intervention of invasive bladder cancer cases may
decrease the number of high stage and lymph node positive cases that have a high risk of local
and distant recurrences. The adjuvant treatment options in the presence of risk factors for
recurrence may improve survival outcomes.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
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Bladder cancer is the second most common tumor in the
urogenital system and one of the most important causes of
mortality and morbidity [1]. Most patients diagnosed with
urothelial carcinoma of the bladder have superficial tu-
mors; yet 20e40% of the patients have muscle and peri-
vesical tissue invasion, even at the beginning. Half of the
patients with invasive tumors already have metastasis, or
metastasis can emerge later on.
Radical cystectomy is the gold standard in the treatment
of muscle-invasive bladder cancer and patients with
noninvasive tumors in whom intravesical therapy failed.
Although radical cystectomy is the gold standard, about
one-third of patients relapse and die from the disease [2].
The main reason for cancer specific mortality in patients
treated with radical cystectomy is related to distant
metastasis. In addition, long-term survival is very rare after
local recurrence. For that reason, it is thought that local
recurrences are as significant as distant metastasis for
disease-specific survival [3].
Recurrences following cystectomy are usually seen in
the 2nd year or 3rd year and their frequencies are 4e29% for
local recurrences and 22e38% for distant metastasis. The
upper urinary system relapse rate is 3e8% and urethral
recurrence rate is 6e10%, which generally develops 2e3
years after cystectomy. Although cisplatin-based chemo-
therapy following recurrences shows relatively positive
response rates, it still has a weak effect on subsequent
survival [3].
The current study evaluated local and systemic recur-
rence patterns in patients treated with radical cystectomy
for urothelial bladder cancer and attempted to define the
predictive factors influencing local and systemic
recurrences.
Methods
Data of 475 patients who underwent radical cystectomy for
invasive bladder cancer in our clinic between 1991 and 2011
were retrospectively analyzed. Criteria for inclusion in the
study were as follows: (1) urothelial carcinoma diagnosis in
the pathological evaluation of the cystectomy specimen;
and (2) the availability of follow-up data in cases after
recurrences. Exclusion criteria were: (1) local or systemic
metastasis at diagnosis; (2) cases of newly developed uro-
thelial carcinomas in the upper urinary system or urethra;
and (3) patients in which primary definitive treatments
failed and who underwent salvage cystectomy. A total of
347 patients met the above criteria and were included in
the study. In the current study, 49 (14.1%) patients had
local recurrences, 96 (27.7%) patients had systemic re-
currences, and 17 (4.9%) cases had both local and systemic
recurrences.
All pathological data were evaluated using a standard
protocol. The American Joint Committee on Cancer 2009
staging system and World Health Organization 1973 grading
system were used [4,5]. Pathological staging is defined as
organ-confined (T0/Ta/TIS/T1/T2, N0), extravesical (T3/
T4, N0), and lymph-node involvement (node-positive) (Any
T, N1e3). Lymph node density (LND) is defined as thenumber of positive lymph nodes divided into the total
number of removed lymph nodes [6]. Primary tumor prop-
erties such as lymphovascular invasion (LVI) and the pres-
ence of concomitant carcinoma in situ (CIS) were recorded.
All patients received a standard surgical procedure
including radical cystectomy, pelvic lymphadenectomy, and
various urinary diversions [1]. All patients who underwent
cystectomy for invasive bladder cancer were followed at 3
month periods for the first 2 years, 6 month periods for 3
years, and annually for the following years. Physical ex-
amination, chest radiography, and blood biochemistry were
routinely performed during follow-up. Intravenous pyelog-
raphy, ultrasonography, and computed tomography were
used in the 3rd month, 6th month, and 12th month after
surgery and annually later on or on the occasion that a
relapse was suspected. Local recurrences were defined as
those occurring within the soft tissue field of exenteration,
which is inside the bony pelvis. Distant recurrences were
those occurring outside the pelvis [1,3]. Time to recurrence
(TTR) was defined as the period from the date of cys-
tectomy to the date when the first recurrence was diag-
nosed; post-recurrence follow-up was the time after the
recurrence (TAR). Post-recurrence disease-specific survival
(PRDSS) graphics are based on TAR.
Independent samples t test was used to determine
relationships between continuous variables. Pearson’s
Chi-square test was used to evaluate categorical vari-
ables. The logrank test and the KaplaneMeier method
were applied for the univariate analysis [7,8]. Multivariate
Cox proportional hazards model was used to calculate
predictive values of independent relationships between
categorical variables that were prognostic in the univari-
ate analysis [7]. Analyses were calculated using SPSS
version 17.0 (SPSS Inc., Chicago, IL, USA). All p values
were two-sided and p  0.05 was considered statistically
significant.Results
A total of 347 patients were included in the study. The
mean patient age at surgery was 61.50  8.87 years. There
were 321 male and 26 female patients. Patient de-
mographic and clinicopathological characteristics are
summarized in Table 1. In the current study, 49 (14.1%)
patients had local recurrence, 96 (27.7%) patients had
systemic recurrence, and 17 (4.9%) cases had both local and
systemic recurrences. The characteristics of patients with
local and systemic recurrences are shown in Table 2.
Local recurrence rates were 8.2% in organ-confined dis-
ease, 17.6% in extravesical disease, and 23.2% in lymph
node positive disease in this study. Systemic metastasis
frequency was 13.5% in organ-confined disease, 39.6% in
extravesical disease, and 45.1% in cases with lymph node
involvement.
Patients were grouped according to recurrence sites
(local, systemic, and local and systemic). Actuarial esti-
mated DSS at 5 years was 28.3% for the local recurrence
group, 0.43% for the systemic metastasis group, and 11.8%
for the both local and systemic recurrence group. Mean DSS
times were 41.07  6.79 months for the local recurrence
group, 18.30  2.03 months for the systemic metastasis
Table 1 Patient demographic and clinicopathological
characteristics.
n %
Mean age 61.50  8.87
Sex Male 321 92.5
Female 26 7.5
Stage Organ-confined 171 49.3
Extravesical 91 26.2
Node-positive 82 23.6
Unknown 3 0.9
Grade 1 6 1.7
2 75 21.6
3 252 72.6
Unknown 14 4.1
CIS Positive 46 13.3
Negative 173 49.9
Unknown 128 36.9
LVI Positive 62 17.9
Negative 157 45.2
Unknown 128 36.9
LND <10% 107 30.8
10% 33 9.5
Unknown 207 59.7
CIS Z carcinoma in situ; LND Z lymph node density;
LVI Z lymphovascular invasion.
506 S. O¨zbir et al.group, and 25.23  4.62 months for the both local and
systemic recurrence group, respectively (p < 0.001, Fig. 1).
Sex, pT stage, lymph node involvement, grade, and LVI
were significantly associated with local recurrence in the
univariate analysis, whereas CIS and LND (10% cut-off
value) had no statistically significant effect in the univari-
ate analysis. In Cox multivariate regression analysis, pT
stage and lymph node involvement were described as pre-
dictors of local recurrence (p < 0.001). Sex, grade, LVI, CIS,
and LND (10% cut-off value) had no predictive effects onTable 2 Characteristics of patients with local and systemic rec
Local recurr
Patient number 49
Mean age 60.71  9.39 (
No. of retrieval LN 12.89  10.51
No. of positive LN 0.95  1.73 (0
LND <10% 26 (53.1)
10% 9(18.4)
Time to recurrence (TTR) 14.37  13.25
CIS positive 8 (16.3)
LVI positive 18 (36.7)
Stage Organ-confined 14 (28.6)
Extravesical 16 (32.7)
Node-positive 19 (38.8)
Grade 1 0
2 2 (4.1)
3 46 (93.9)
Data are presented as n (%) or mean  SD (range), unless otherwise
CIS Z carcinoma in situ; LN Z lymph node; LND Z lymph node denslocal recurrence in the multivariate analysis. Univariable
and multivariable analysis results of the parameters that
affected local recurrence are shown in Table 3.
Systemic metastasis was found in 96 cases, including 29
in lungs, 25 in bones, and 23 in the liver. Other organ
metastasis such as the brain, skin, penis, and peritoneal
cavity were less frequent. The pT stage, lymph node
involvement, grade, LVI, and LND (10% cut-off value) were
significantly associated with systemic metastasis in the
univariate analysis, whereas sex and CIS had no statistically
significant effect in the univariate analysis. In the Cox
multivariate regression analysis, pT stage and lymph node
involvement were described as predictors of systemic
metastasis (p < 0.001). Sex, grade, LVI, CIS, and LND (10%
cut-off value) had no predictive effects on systemic
metastasis in the multivariate analysis. Univariable and
multivariable analysis results of the parameters that
affected the systemic metastasis are shown in Table 4.
In this series, 32 patients in the local recurrence group
and 79 patients in the systemic recurrence group received
adjuvant chemotherapy after radical cystectomy. Univari-
ate analysis demonstrated that chemotherapy does not
decrease the rate of local (p Z 0.113) and systemic
(p Z 0.793) recurrence rates.
TTR was defined as the period from the date of cys-
tectomy to the date when the first recurrence was diag-
nosed; post-recurrence follow-up was the TAR. Post-
recurrence disease specific survival (PRDSS) graphics are
based on TAR. Mean TAR were 14.37  13.25 months (range,
2e60 months) in local recurrence and 14.43  15.72 months
(range, 2e109 months) for systemic metastasis. The post-
recurrence follow-up was calculated in order to achieve
PRDSS rates according to recurrence sites. Actuarial esti-
mated PRDSS at 1 year was 74.9% for the local recurrence
group, 0.39% for the systemic metastasis group, and 41.2%
for the both local and systemic recurrence group. Mean
PRDSS times were 17.82  3.18 months for the local
recurrence group, 4.16  0.39 months for the systemic
metastasis group, and 11.41  2.73 months for the bothurrences.
ence Systemic metastasis p
96
42e82) 61.73  8.14 (42e80) 0.610
(0e34) 11.24  8.18 (1e30) 0.389
e7) 1.76  2.94 (0e13) 0.113
19 (19.8) 0.007
15 (15.6)
(2e60) 14.43  15.72 (2e109) 0.808
13 (13.5) 0.661
25 (26) 0.712
23 (24) 0.244
36 (37.5)
37 (38.5)
2 (2) 0.411
10 (10.4)
82 (85.4)
indicated.
ity; LVI Z lymphovascular invasion; TTR Z time to recurrence.
Table 4 Univariate and multivariate analyses of parame-
ters predicting systemic recurrence.
Parameter Univariate p Multivariate p
Sex 0.220 0.986
Stage <0.001 <0.001
Lymph node involvement <0.001 <0.001
Grade <0.001 0.069
Presence of CIS 0.423 0.495
Presence of LVI <0.001 0.403
LND (<10% vs. 10%) <0.001 0.839
CIS Z carcinoma in situ; LND Z lymph node density;
LVI Z lymphovascular invasion.
Figure 1. KaplaneMeier curve demonstrating disease-
specific survival in patients stratified by recurrence site.
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Median PRDSS times were 12 months for local recurrence, 3
months for systemic metastasis, and 7 months for both local
and systemic recurrence.
Discussion
Bladder cancer is the second most common urological
cancer following prostate cancer [9e17]. A total of 20e40%
patients have the invasive disease even at the time of
diagnosis [2,4]. Invasive bladder cancer is such a lethal
disease requiring aggressive treatment that when left un-
treated, in 2 years, fewer than 15% of patients are able to
survive [11]. Most of the patients who developed re-
currences following radical cystectomy die within 15
months, and very few of them may survive for 4 years [3].
Local recurrence after radical cystectomy is generally
located in the pelvic soft tissues or pelvic lymph nodes. The
possible mechanisms for local recurrence development are:
incomplete excision of tumor, positive surgical margins,
insufficient pelvic lymph node dissection, and spillage of
tumor cells during operation [16,18]. Before the usage of
advanced imaging techniques such as computed tomogra-
phy, local recurrences following radical cystectomies were
rarely diagnosed [12]. Cole et al. [17] showed that localTable 3 Univariate and multivariate analyses of parame-
ters predicting local recurrence.
Parameter Univariate p Multivariate p
Sex 0.012 0.269
pT stage <0.001 <0.001
Lymph node involvement <0.001 <0.001
Grade <0.001 0.114
Presence of CIS 0.488 0.752
Presence of LVI <0.001 0.638
LND (<10% vs. 10%) 0.059 0.057
CIS Z carcinoma in situ; LND Z lymph node density
LVI Z lymphovascular invasion.relapses were more common than previously thought. As
advanced imaging techniques become more accessible,
there is an increase in the diagnosis of recurrences. Re-
currences following cystectomy are usually seen in the 2nd
year or 3rd year and their frequencies range between 4%
and 29% in local recurrences and 22% and 38% for distant
metastasis. [2,3,12e17]. For all recurrences, 3e8% are
upper urinary system relapses and 6e10% are urethral re-
currences, which developed 2e3 years after cystectomy
and are thought to originate from dysregulated extravesical
urothelium [3].
In the current study, 49 (14.1%) patients had local re-
currences, 96 (27.7%) patients had systemic recurrences,
and 17 cases (4.9%) had both local and systemic re-
currences. These results are similar to those in the litera-
ture [12e17]. Local recurrences are usually seen 2e3 years
after radical cystectomy. In the current study, mean TTR
were 14.37  1325 months (range, 2e60 months) for local
recurrence and 14.43  15.72 months (range, 2e109
months) for systemic metastasis. Although there are new
developments for the treatment of invasive bladder cancer,
prognosis after local recurrences is not good because of the
aggressive nature of these tumors. Therefore, it is very
important to diagnose recurrences as early as possible by
using different contemporary imaging techniques and
determining the possible risk factors.Figure 2. KaplaneMeier curve demonstrating post-
recurrence disease-specific survival (PRDSS) in patients strati-
fied by recurrence site.
Table 6 Local and systemic recurrence rates after radical
cystectomy stratified by pathologic stage.
Local
recurrence
(%)
Stein
[1] (%)
Hautmann
[16] (%)
Mardersbacher
[14] (%)
Our
study
(%)
Organ-confined 6 4 NA 8.2
Extravesical 13 15.9 NA 17.6
LN positive 13 20.4 13 23.2
Systemic recurrence (%)
Organ-confined 13 9.5 25 13.5
Extravesical 32 19.2 37 39.6
LN positive 52 45.1 49 45.1
LN Z lymph node; NA Z not available.
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involvement were the most important predictive factors for
both local and metastatic recurrences. These findings are
similar in different series. Local recurrences rates and
prognostic factors in patients after radical cystectomy in
the variable series are shown in Table 5. In the current
study, local recurrence rates were 8.2% in organ-confined
disease, 17.6% in extravesical disease, and 23.2% in lymph
node positive disease. Systemic metastasis frequency was
13.5% in organ-confined disease, 39.6% in extravesical dis-
ease, and 45.1% in cases with lymph node involvement.
There are various studies to determine the prognostic fac-
tors on local recurrence. Factors related to local recur-
rence are stage, lymph node involvement, extent of
lymphadenectomy, and perioperative chemotherapy in one
study [16]. Extravesical disease and lymph node involve-
ment increase the risk of both local and systemic recur-
rence rates in most series [1,6,14,15]. Greven et al. [19]
found that local recurrence rates were 6% for stage pT1,
18% for stage pT3a, and 51% for stage pT3b. The results of
the current study for local and systemic recurrence ac-
cording to the stages were similar to the series in the
literature (Table 6).
Ide et al. [2] showed that local recurrence is an inde-
pendent predictor of systemic metastasis and DSS. Like-
wise, Pollack et al. [20] reported that local recurrence with
pT stage and lymph node involvement were predictive
factors for DSS. The current study revealed that the pre-
dictive factors on both local and systemic recurrences were
stage and lymph node involvement. Furthermore, Greven
et al. [19] and Pollack et al. [20] reported stage as a local
recurrence predictor on their studies. Ide et al. [2]Table 5 Local recurrence rates and prognostic factors
after radical cystectomy in variable series.
Studies Local recurrence
rate (%)
Prognostic
factor
Brendler [16] 3/76 (3.9) NA
Stein [16] 77/1054 (7.3) NA
Volkmer [16] 182/1270 (14.3) NA
Fraizer [16] 50/531 (9.4) NA
Cheng [16] 63/218 (28.8) NA
Greven [19] 13/83 (15.7) Stage
Pollack [20] 30/228 (13.2) Stage
Herr [15] 51/322 (15.8) No. of retrieved
lymph nodes (<8)
Honma [12] 27/145 (18.6) Concomitant SCC
component/pure SCC
Ide [2] 26/146 (17.8) Concomitant AC
component
Lymph node
involvement
No. of retrieved lymph
nodes (<8)
Current
study
49/347 (14.1) Stage, lymph node
involvement
AC Z adenocarcinoma; NA Z not available; SCC Z squamous
cell carcinoma.described local recurrence predictors as lymph node
involvement, removed lymph node number (<8), and
concomitant adenocarcinoma component. There are also
various studies that reported lymph node involvement as a
predictive for DSS [6,15,21]. Honma et al. [12] reported
that the single prognostic factor that affects local recur-
rence is concomitant squamous cell carcinoma (SCC) or
pure SCC histology. Herr et al. [15] and Ide et al. [2] re-
ported that the removal of less than eight lymph nodes has
a prognostic value on recurrence. The current study
included only cases with urothelial carcinoma histology and
did not aim for a prognostic value of the number of lymph
nodes removed. Instead, the study set the threshold value
for the LND variable as 10%. In the univariate analysis
regarding systemic metastasis, LND (<10% vs. 10%) had a
predictive effect on survival, but in the multivariable
analysis, LND (<10% vs. 10%) was not a predictor on
survival.
In the current study, 49 (14.1%) patients had local
recurrence, 96 (27.7%) patients had systemic recurrence,
and 17 (4.9%) cases had both local and systemic re-
currences. Mean TTR were 14.37  13.25 months in local
recurrence and 14.43  15.72 months for systemic metas-
tasis in this study, which is similar to the results found in
the literature (1,3,14). Median TTR in reported series are
between 9 months and 18 months, but typically < 12
months, which is a relatively short period [19,22,23].
Westney et al. [23] reported that 82% of the cases (27/33)
developed local recurrence within 2 years in a review of
their clinic’s experience with local recurrences over 35
years. Most recurrences developed within the first 2e3
years in patients who underwent radical surgery, but some
recurrences can be observed later. Therefore, it is impor-
tant that close monitoring with strict follow-up protocols,
especially in the first 2e3 years, is important for earlier
diagnosis of possible recurrences, increasing the efficiency
of other treatment options and better prognosis.
The current study used post-recurrence follow-up in
order to achieve PRDSS rates according to recurrence sites.
Actuarial estimated PRDSS at 1 year was 74.9% for the local
recurrence group, 0.39% for the systemic metastasis group,
and 41.2% for the both local and systemic recurrence group,
respectively. Mean PRDSS times were 17.82  3.18 months
for the local recurrence group, 4.16  0.39 months for the
systemic metastasis group, and 11.41  2.73 months for the
Table 7 Post-recurrence disease-specific survival (PRDSS)
median times according to site of recurrence.
Mitra et al. [3]
(median)
Our study
(median)
Local 7.95 (5.45; 10.46) 12 (5.21; 18.78)
Systemic 5.95 (4.95; 6.94) 3 (2.46; 3.53)
Local and
systemic
3.98 (2.87; 5.09) 7 (0.00; 16.41)
Recurrences after radical cystectomy 509both local and systemic recurrence group, respectively
(p < 0.001). Only Mitra et al. [3] did an extensive study on
PRDSS parameters and reported PRDSS median times ac-
cording to site recurrences. PRDSS median times of both
studies are summarized in Table 7.
The current study had some limitations. Although this is
one of the longest series in Turkey, retrospective design,
single center experience, and insufficient data about post-
recurrence treatment protocols makes it more difficult to
evaluate the efficiency of post-recurrence treatment pro-
tocols and their effects on survival. A prospective study
without these limitations could show the results that can
aid the decision making process more clearly. Researching
the prognostic factors that influence recurrences are
important for the early diagnosis of recurrences and con-
trolling them in a group of patients, reducing the risk of
possible distant metastasis and better survival. In order to
achieve local control, aggressive excision of neighboring
tissues around the bladder, extended lymph node dissec-
tion, and adjuvant treatment protocols should be kept in
mind.
This study found that stage and lymph node involvement
were prognostic factors for both local and systemic re-
currences. On the basis of these results, adjuvant therapy
options must be taken into account in the presence of
extravesical disease and lymph node involvement.
In conclusion, early diagnosis, close monitoring, and
extended lymph node dissection regarding the prognostic
value of lymph node involvement and usage of adjuvant
therapies in extravesical and lymph node involved diseases
would be beneficial to improve both local and systemic
control of the disease.References
[1] Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S,
et al. Radical cystectomy in the treatment of invasive bladder
cancer: long-term results in 1,054 patients. J Clin Oncol 2001;
19:666e75.
[2] Ide H, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T,
Nakashima J, et al. The predictors of local recurrence after
radical cystectomy in patients with invasive bladder cancer.
Jpn J Clin Oncol 2008;38:360e4.
[3] Mitra AP, Quinn DI, Dorff TB, Skinner EC, Schuckman AK,
Miranda G, et al. Factors influencing post-recurrence survival
in bladder cancer following radical cystectomy. BJU Int 2010;
109:846e64.[4] Urinary bladder. In: Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG, et al., editors. AJCC cancer staging
manual. 6th ed. New York: Springer; 2002. pp. 367e74.
[5] Mostofi FK, Sobin HL, Torlini H. Histologic typing of urinary
bladder tumors. Geneva: World Health Organization; 1973.
[6] Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients
with pelvic lymph node metastases following radical cys-
tectomy with en bloc pelvic lymphadenectomy: concept of
lymph node density. J Urol 2003;170:35e41.
[7] Miller RG, Gong G, Munoz A. Survival analysis. New York:
Wiley; 1981.
[8] Kaplan EL, Meier P. Nonparametric estimation from incom-
plete observations. J Am Stat Assoc 1958;53:457e81.
[9] Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A,
et al. Cancer statistics 2005. CA Cancer J Clin 2005;55:10e30.
[10] Canadian Cancer Society/National Cancer Institute of Canada:
Canadian Cancer Statistics 2008. Toronto: Canada; 2008.
[11] Prout GR, Marshall VF. The prognosis with untreated bladder
tumors. Cancer 1956;9:551e8.
[12] Honma I, Masumori N, Sato E, Takayanagi A, Takahashi A,
Itoh N, et al. Local recurrence after radical cystectomy for
invasive bladder cancer: an analysis of predictive factors.
Urology 2004;64:744e8.
[13] Stein JP, Skinner DG. Radical cystectomy for invasive bladder
cancer: long-term results of a standard procedure. World J
Urol 2006;24:296e304.
[14] Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN,
Danuser H, Markwalder R, et al. Radical cystectomy for
bladder cancer today e a homogeneous series without neo-
adjuvant therapy. J Clin Oncol 2003;21:690e6.
[15] Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE,
Bajorin DF. Impact of the number of lymph nodes retrieved on
outcome in patients with muscle invasive bladder cancer. J
Urol 2002;167:1295.
[16] Cagiannos I, Morash C. Surveillance strategies after definitive
therapy of invasive bladder cancer. Can Urol Assoc J 2009;
3(Suppl. 4):S237e42.
[17] Cole CJ, Pollack A, Zagars GK, Dinney CP, Swanson DA, von
Eschenbach AC. Local control of muscle-invasive bladder
cancer: preoperative radiotherapy and cystectomy versus
cystectomy alone. Int J Radiat Oncol Biol Phys 1995;32:
331e40.
[18] Pisters L, Westney L. The management of locally recurrent
invasive bladder cancer following radical cystectomy. Semin
Urol Oncol 1996;14:112e9.
[19] Greven KM, Spera JA, Solin LJ, Morgan T, Hanks GE. Local
recurrence after cystectomy alone for bladder carcinoma.
Cancer 1992;69:2767e70.
[20] Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA,
Grossman HB. The relationship of local control to distant
metastasis in muscle invasive bladder cancer. J Urol 1995;154:
2059e63.
[21] Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H,
et al. Cystectomy for bladder cancer: a contemporary series.
J Urol 2001;165:1111e6.
[22] Schoenberg MP, Walsh PC, Breazeale DR, Marshall FF,
Mostwin JL, Brendler CB. Local recurrence and survival
following nerve sparing radical cystoprostatectomy for
bladder cancer: 10-year follow-up. J Urol 1996;155:490e4.
[23] Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A,
Dinney CP. Presentation, methods of diagnosis and therapy for
pelvic recurrence following radical cystectomy for transitional
cell carcinoma of the bladder. J Urol 1998;159:792e5.
